Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential

Decision Diagnostics Corp.

Companies Mentioned:

Primary Exchange: OTC:BB
Under the Symbol: DECN

Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential

Tuesday, October 22, 2013 12:36 PM

Los Angeles, CA - (October 22, 2013) Decision Diagnostics Corp. (OTCBB: DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip[TM], the unique diabetes monitoring Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (JNJ) LifeScan Ultra family of glucose testing meters has been the focus of favorable articles and papers published recently. Today BioMedReports released an article on the front page of their website titled “DECN Set to Climb as GenStrip Enters Blood Glucose Monitoring Market With New Large Shipments.”  The article summarizes DECN’s history and current business.  The full article can be read here:

Decision Diagnostics has also been featured in articles in Forbes, Qmed and Seeking Alpha in the past few months.  All of these articles are available online on their respective websites. 

Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, “Decision Diagnostics has begun shipping large box quantities of Shasta GenStrip glucose monitoring test strips and we are pleased that the disruptive market potential of the product line is being recognized and written upon by financial and healthcare publication.”

About BioMedReports is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.  Visit

About Decision Diagnostics:

DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. DECN's FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.

Forward-Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information about Shasta Genstrip, please visit the company's web sites: or

GenStrip[TM] test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan[R], Inc. a Johnson & Johnson[R] Company, manufacturers and distributors of the OneTouch[R] Ultra[R] Family of Meters and OneTouch[R] Ultra[R] test strips.



Decision Diagnostics Corp.

Keith Berman
(805) 446-2973

[email protected]